

Company Number: 165497

**Emmet Feerick Pharmacy Limited**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 28 February 2025**

# Emmet Feerick Pharmacy Limited

## CONTENTS

	<b>Page</b>
Directors and Other Information	3
Directors' Responsibilities Statement	4
Statement of Financial Position	5
Statement of Changes in Equity	6
Notes to the Financial Statements	7 - 11

# Emmet Feerick Pharmacy Limited

## DIRECTORS AND OTHER INFORMATION

<b>Directors</b>	Emmet Feerick Maire Feerick
<b>Company Secretary</b>	Emmet Feerick
<b>Company Number</b>	165497
<b>Registered Office</b>	c/o Thomas P. Fox & Co. Leixlip Centre Leixlip Co. Kildare
<b>Business Address</b>	1 Riverforest Court Riverforest SC Leixlip Co. Kildare
<b>Accountants</b>	Thomas P Fox & Co Accountants Leixlip Centre Leixlip Co Kildare W23FW40
<b>Bankers</b>	AIB Bank Main Street Leixlip Co. Kildare  Bank of Ireland Leixlip Co. Kildare
<b>Solicitors</b>	O' Reilly Timmins & Co. Pound Street Leixlip Co. Kildare

# Emmet Feerick Pharmacy Limited

## DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 28 February 2025

The directors made the following statement in respect of the unaudited financial statements:

### "General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Statement of Financial Position, the Statement of Changes in Equity and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to Thomas P Fox & Co, (Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 28 February 2025."

### Signed on behalf of the board

**Emmet Feerick**  
Director

19 November 2025

**Maire Feerick**  
Director

19 November 2025

# Emmet Feerick Pharmacy Limited

## STATEMENT OF FINANCIAL POSITION

as at 28 February 2025

	Notes	2025 €	2024 €
<b>Non-Current Assets</b>			
Property, plant and equipment	7	79,693	87,577
<b>Current Assets</b>			
Stocks	8	61,255	58,461
Debtors	9	200,650	191,449
Cash and cash equivalents		543,889	534,920
		805,794	784,830
<b>Creditors: amounts falling due within one year</b>	10	(136,192)	(137,283)
<b>Net Current Assets</b>		669,602	647,547
<b>Total Assets less Current Liabilities</b>		749,295	735,124
<b>Provisions for liabilities</b>	12	4,649	(2,348)
<b>Net Assets</b>		753,944	732,776
<b>Capital and Reserves</b>			
Called up share capital presented as equity	13	2,200	2,200
Retained earnings		751,744	730,576
<b>Equity attributable to owners of the company</b>		753,944	732,776

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Emmet Feerick Pharmacy Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

**Approved by the board on 19 November 2025 and signed on its behalf by:**

**Emmet Feerick**  
Director

**Maire Feerick**  
Director

**Emmet Feerick Pharmacy Limited**  
**STATEMENT OF CHANGES IN EQUITY**

as at 28 February 2025

	<b>Called up share capital €</b>	<b>Retained earnings €</b>	<b>Total €</b>
<b>At 1 March 2023</b>	2,200	627,840	630,040
Profit for the financial year	-	102,736	102,736
<b>At 29 February 2024</b>	2,200	730,576	732,776
Profit for the financial year	-	21,168	21,168
<b>At 28 February 2025</b>	<b>2,200</b>	<b>751,744</b>	<b>753,944</b>

# Emmet Feerick Pharmacy Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 28 February 2025

### 1. General Information

Emmet Feerick Pharmacy Limited is a company limited by shares incorporated in Ireland. c/o Thomas P. Fox & Co., Leixlip Centre, Leixlip, Co. Kildare is the registered office. The registered number of the company is 165497. The principal place of business of the company is 1 Riverforest Court, Riverforest SC, Captains Hill, Leixlip, Co. Kildare. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

#### Statement of compliance

The financial statements of the company for the year ended 28 February 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

#### Turnover

Turnover represents net sales to customers and excludes Value Added Tax and similiar taxes and derives from the provision of goods falling within the company's ordinary activities.

#### Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of property, plant and equipment, less their estimated residual value, over their expected useful lives as follows:

Long leasehold property	-	10% Straight Line
Fixtures, fittings and equipment	-	12.5% Reducing Balance
Motor vehicles	-	12.5% Straight Line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### Stocks

Stocks are valued at the lower of cost and net realisable value. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

#### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

#### Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Statement of Financial Position bank overdrafts are shown within Creditors.

# Emmet Feerick Pharmacy Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 28 February 2025

### Borrowing costs

All borrowing costs are recognised in profit or loss in the period in which they are incurred.

### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

### Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

### Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

### Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Income Statement annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Income Statement when received.

### Ordinary share capital

The ordinary share capital of the company is presented as equity.

### 3. Turnover

The whole of the company's turnover is attributable to its market in the Republic of Ireland and is derived from the principal activity of pharmacist.

<b>4. Operating profit</b>	<b>2025</b>	2024
	€	€
<b>Operating profit is stated after charging/(crediting):</b>		
Depreciation of property, plant and equipment	<b>12,405</b>	13,021
(Profit)/loss on disposal of property, plant and equipment	-	3,445
Government grants received	<b>(4,000)</b>	-
	<u>          </u>	<u>          </u>
<b>5. Interest payable and similar expenses</b>	<b>2025</b>	2024
	€	€
Interest	<b>8</b>	261
	<u>          </u>	<u>          </u>

## Emmet Feerick Pharmacy Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 28 February 2025

### 6. Employees

The average monthly number of employees, including directors, during the financial year was 7, (2024 - 6).

	2025 Number	2024 Number
Directors	2	2
Sales and administration	5	4
	<u>7</u>	<u>6</u>

### 7. Property, plant and equipment

	Long leasehold property €	Fixtures, fittings and equipment €	Motor vehicles €	Total €
<b>Cost</b>				
At 1 March 2024	35,734	176,287	14,959	226,980
Additions	-	4,521	-	4,521
At 28 February 2025	<u>35,734</u>	<u>180,808</u>	<u>14,959</u>	<u>231,501</u>
<b>Depreciation</b>				
At 1 March 2024	14,292	110,152	14,959	139,403
Charge for the financial year	3,573	8,832	-	12,405
At 28 February 2025	<u>17,865</u>	<u>118,984</u>	<u>14,959</u>	<u>151,808</u>
<b>Net book value</b>				
At 28 February 2025	<u><b>17,869</b></u>	<u><b>61,824</b></u>	<u>-</u>	<u><b>79,693</b></u>
At 29 February 2024	<u>21,442</u>	<u>66,135</u>	<u>-</u>	<u>87,577</u>

### 8. Stocks

	2025 €	2024 €
Finished goods and goods for resale	<u><b>61,255</b></u>	<u>58,461</u>

The replacement cost of stock did not differ significantly from the figures shown.

### 9. Debtors

	2025 €	2024 €
Trade debtors	<b>86,240</b>	88,957
Other debtors	<b>25,264</b>	22,110
Directors' current accounts	<b>11,433</b>	7,103
Taxation and social welfare	<b>56,531</b>	56,303
Prepayments	<b>21,182</b>	16,976
	<u><b>200,650</b></u>	<u>191,449</u>

Directors' current accounts are unsecured, interest free and repayable on demand.

## Emmet Feerick Pharmacy Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 28 February 2025

<b>10. Creditors</b>	<b>2025</b>	<b>2024</b>
<b>Amounts falling due within one year</b>	<b>€</b>	<b>€</b>
Amounts owed to credit institutions	816	323
Trade creditors	99,588	81,431
Taxation and social welfare	27,779	48,326
Other creditors	416	-
Accruals	7,593	7,203
	<u>136,192</u>	<u>137,283</u>

Trade creditors include amounts owing to suppliers, who purport to include reservation of title clauses in their conditions of sales. It is not practicable to quantify this amount, or how much of it is included in stocks.

<b>11. Taxation and social welfare</b>	<b>2025</b>	<b>2024</b>
	<b>€</b>	<b>€</b>
<b>Debtors:</b>		
Withholding tax	56,531	56,303
<b>Creditors:</b>		
VAT	2,185	7,801
Corporation tax	6,697	22,562
PAYE	15,561	17,963
PRSI	3,336	-
	<u>27,779</u>	<u>48,326</u>

## 12. Provisions for liabilities

The amounts provided for deferred taxation are analysed below:

	Capital allowances	Other differences	Total	Total
	€	€	2025 €	2024 €
At financial year start	2,348	-	2,348	2,294
Charged to profit and loss	503	(7,500)	(6,997)	54
At financial year end	<u>2,851</u>	<u>(7,500)</u>	<u>(4,649)</u>	<u>2,348</u>

<b>13. Share capital</b>			<b>2025</b>	<b>2024</b>
			<b>€</b>	<b>€</b>
<b>Description</b>	<b>Number of shares</b>	<b>Value of units</b>		
<b>Authorised</b>				
Ordinary Shares Class 1	1,000,000	€2.00 each	<u>2,000,000</u>	<u>2,000,000</u>
<b>Allotted, called up and fully paid</b>				
Ordinary Shares Class 1	1,100	€2.00 each	<u>2,200</u>	<u>2,200</u>

**Emmet Feerick Pharmacy Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 28 February 2025

The directors' and the secretary's interests in the shares of the company are as follows:-

Name	Class of Shares	Number Held	
		At 28/02/25	01/03/24
Emmet Feerick	Ordinary Shares Class 1	550	550
Maire Feerick	Ordinary Shares Class 1	550	550
		<u>1,100</u>	<u>1,100</u>

**14. Income Statement**

	2025 €	2024 €
At 1 March 2024	730,576	627,840
Profit for the financial year	21,168	102,736
At 28 February 2025	<u>751,744</u>	<u>730,576</u>

**15. Directors' remuneration**

	2025 €	2024 €
Remuneration	356,462	222,318
Pension contributions	30,000	64,109
	<u>386,462</u>	<u>286,427</u>

**16. Related party transactions**

Allied Irish Banks plc hold two letters of guarantee in the amounts of € 30,000 each in the names of the directors of the company.

**17. Events After the End of the Reporting Period**

There have been no significant events affecting the company since the financial year-end.

**18. Approval of financial statements**

The financial statements were approved and authorised for issue by the board of directors on 19 November 2025.